Weight Loss · GLP-1 Program
Get compounded semaglutide prescribed by licensed US providers and prepared by state-licensed compounding pharmacies. Bilingual intake forms and care coordination. From $199/month, all-inclusive. Compounded semaglutide is not FDA-approved and is not a generic version of Ozempic® or Wegovy®.
The science
Semaglutide is a GLP-1 receptor agonist that mimics a natural hormone to regulate appetite and metabolism.
Signals the brain to eat less and feel full longer.
Slows food movement through the digestive system.
Regulates glucose levels and reduces cravings.
Creates lasting fullness from smaller meals.
Treatment plan
Provider-supervised dose escalation over 20 weeks to maximize results and minimize side effects.
Weeks 1–4
0.25 mg
Starter dose weekly
Weeks 5–8
0.5 mg
Increased weekly
Weeks 9–16
1.0 mg
Therapeutic dose
Weeks 17+
2.0 mg
Maintenance dose
Injection method
Subcutaneous (under the skin)
Frequency
Once per week
Provider check-ins
Monthly dose adjustments
Timeline
20 weeks to full dose
What to expect
Weight loss milestones and what patients typically experience at each phase.
Week 2–4
Noticeable decrease in hunger and food cravings.
Month 2–3
Weight loss becomes visible; clothes fit differently.
Month 4–6
Average body weight reduction of 10–15%.
Month 6+
Continued loss with maintenance dose.
Results vary based on adherence, diet, exercise, and individual metabolism. Your REMEVi licensed provider will monitor your progress and adjust dosing as needed.
All-inclusive
Unlike Hims, Ro, and Medvi — there are no hidden lab fees or add-on charges.
Board-certified US clinical reviews your health history and creates your personalized plan.
High-quality compounded semaglutide from an FDA-registered pharmacy.
Medication shipped directly to your door in unmarked packaging. Free every month.
Dedicated coordinator available in English and Spanish with a 2-hour response SLA.
Regular check-ins with your care team to adjust dosage and monitor your progress.
Manage your subscription, message your care team, and track your progress online.
Same price every month for the length of your plan. No "first-month special." No surprise increases. The price you see is the price you pay — for as long as you are a patient.
Provider-managed weekly injection. The same compounded GLP-1 as the big-brand competitors — with bilingual care, no insurance, no surprise increases.
Daily oral semaglutide. Same clinical oversight, same bilingual care — without the needle.
Dual-agonist tirzepatide. The strongest average loss in the GLP-1 category — provider-managed, bilingual care.
¹ Clinical-trial results for semaglutide (STEP-1, NEJM 2021) and tirzepatide (SURMOUNT-1, NEJM 2022) — the active medications in REMEVi protocols, not REMEVi outcomes or guarantees. Compounded preparations are not FDA-approved and have not been studied as finished products. Individual results vary.
REMEVi's semaglutide is compounded by a 503B outsourcing facility registered with the FDA — the same regulatory tier hospitals use. Compounded medications are not FDA-approved finished drug products; they are prepared under the 503A or 503B framework to USP <797> sterility standards and prescribed by a licensed provider in your state who will review the risks, benefits, and considerations with you.
FAQ
Semaglutide is a GLP-1 receptor agonist — a medication that mimics the glucagon-like peptide-1 hormone. It works by reducing appetite, slowing stomach emptying, and improving blood sugar control. Originally developed for type 2 diabetes, the GLP-1 class has been extensively studied for weight management.
Compounded medications are not FDA-approved finished drug products. They are prepared under the 503A or 503B regulatory framework by state-licensed compounding pharmacies and are subject to USP standards. Every REMEVi patient is evaluated by a licensed provider before any medication is dispensed, and your provider will review the risks, benefits, and contraindications of compounded semaglutide with you before prescribing.
The most common side effects are nausea, vomiting, diarrhea, and constipation — especially when starting or increasing the dose. These typically resolve within a few weeks. Serious side effects are rare; your licensed provider will discuss all risks during your evaluation.
Most patients notice reduced appetite within the first 2–4 weeks. Meaningful weight loss typically begins at weeks 4–8 as the dose increases. Average results at 6 months range from 10–20% body weight reduction depending on lifestyle factors.
GLP-1 medications can be used long-term under your provider's supervision. Many patients maintain a lower dose after reaching their goal weight. Your REMEVi licensed provider will create a sustainable long-term plan with you.
5-minute intake. Clinical review within 24 hours. Medication shipped free.
Start free consult — from $199/moNo insurance required · Cancel anytime
